医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cerveau Technologies, Inc. Signs Research Agreement with Houston Methodist

2017年11月08日 PM11:02
このエントリーをはてなブックマークに追加


 

BOSTON

Cerveau Technologies Inc. today announced an agreement with Houston Methodist Hospital to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

As part of the agreement, Cerveau will contract with Houston Methodist to manufacture and supply the [18F]MK-6240 needed for the initiatives in the greater Houston area as well as support research initiatives at Houston Methodist.

According to Dr. Joseph C. Masdeu, director of Houston Methodist’s Nantz National Alzheimer Center, “this new tau PET tracer could help us better understand the nature of neurodegenerative diseases, such as Alzheimer’s, and monitor the effects of existing and new therapies.”

“Cerveau welcomes this opportunity to work with Houston Methodist researchers to understand the application of MK-6240 and how it may benefit patients with this devastating disease. The collaboration with Houston Methodist will provide access to our pharmaceutical partners in support of various therapy trials as well facilitate novel research at Houston Methodist in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.

About Houston Methodist
The Houston Methodist Neurological Institute advances the discovery of the origins, mechanisms and treatment of neurological disease and provides comprehensive care for patients with disorders and injuries of the brain and spinal cord. The institute houses the practice and research activities of the departments of neurology, neurosurgery, neuroradiology, neurophysiology, and physical medicine and rehabilitation at Houston Methodist.

About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005920/en/

CONTACT

Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者